BioVie Achieves Parkinson's Trial Milestone, Discusses Data Integrity in Research

Parkinson's Trial Enrollment Milestone

• 🚀 BioVie has announced the full enrollment of its clinical trial for Parkinson's disease, evaluating its drug candidate, BeziStrum.
• 🎯 This milestone positions the company to release top-line data in the April-May timeframe, potentially offering a new therapy after 50 years.

BeziStrum's Efficacy and Novel Approach

• 💡 Earlier trials showed that BeziStrum, when combined with Levodopa, improved muscle control and morning mobility in Parkinson's patients.
• 🔑 The current trial aims to demonstrate that BeziStrum, administered alone, can delay disease progression in patients newly starting therapy.
• 🏠 BioVie employed an innovative in-home clinical trial model, sending skilled individuals to patients' homes to conduct examinations and video recordings, improving recruitment and diversity.

Addressing Data Integrity in Clinical Research

• ⚠️ BioVie publicly disclosed issues with protocol deviations and good clinical practices at 15 of its Alzheimer's trial sites, reporting them to the FDA.
• 📢 This transparency, along with similar actions by Bristol Myers Squibb, T3D, and Novartis, aims to highlight a growing problem of misconduct in clinical research sites.
• ⚖️ The company hopes that increased awareness will prompt more aggressive investigative and enforcement actions from the FDA and Department of Justice.
• 🤝 The integrity of medical research relies on trust, and BioVie advocates for a more serious industry-wide approach to addressing these issues.